ASTRALS Misses Phase II ALS Endpoints

Company Novartis Event Type Phase II Trial Failure / Program Discontinuation Modality TREM2-Stabilizing Monoclonal Antibody Asset VHB937 (Lifonebart) Target TREM2 Disease Area Amyotrophic Lateral Sclerosis Summary Novartis discontinued VHB937, also known as lifonebart, in amyotrophic lateral sclerosis after the 251-participant Phase II ASTRALS study missed…